Agreement

SciSparc to Acquire AutoMax

Retrieved on: 
Thursday, April 11, 2024
Agreement, Disorder, Acquisition, TEL, Combined, Central nervous system

According to the Agreement, the Company will acquire 100% of AutoMax and establish a new wholly-owned Israeli subsidiary, which would in turn merge with and into AutoMax (the “Acquisition”).

Key Points: 
  • According to the Agreement, the Company will acquire 100% of AutoMax and establish a new wholly-owned Israeli subsidiary, which would in turn merge with and into AutoMax (the “Acquisition”).
  • As a result of the Acquisition, all outstanding shares of AutoMax will be converted into the right to receive ordinary shares of SciSparc.
  • The Acquisition is subject to various approvals, including compliance with any regulatory requirements, including certain Israeli court approvals and SciSparc and AutoMax shareholder approvals.
  • Mr. Amitai Weiss, the chairman of SciSparc, is also the chairman of AutoMax.

Hyliion and BayoTech Partner to Provide Sustainable Power with Hydrogen Hubs and the KARNO™ Generator

Retrieved on: 
Thursday, April 25, 2024
Climate Change, Other Energy, Transport, Utilities, Green Technology, Coal, Logistics, Supply Chain Management, Alternative Energy, Environment, Energy, Sustainability, Hydrogen, Agreement, Partnership, Electricity, Carbon, Renewable energy

Recognizing the complementary nature of their products and customer needs, the companies have entered into the Agreement to support the advancement of sustainable power generation using hydrogen.

Key Points: 
  • Recognizing the complementary nature of their products and customer needs, the companies have entered into the Agreement to support the advancement of sustainable power generation using hydrogen.
  • Hyliion's innovative KARNO generator, which can operate on multiple fuel types including hydrogen, is designed for a variety of applications such as prime power, renewables matching, and for energy arbitrage.
  • BayoTech’s BayoGaaS® hydrogen production hubs and their highly efficient, high-pressure transport trailers and storage units aim to ensure a reliable hydrogen supply chain for customers.
  • This partnership will enhance the product offerings of both companies, supporting the shift towards more sustainable power solutions across industries.

Mountain Valley MD Announces Acquisition of Exclusive License for Agrarius, Launch of Performance Guarantee Program

Retrieved on: 
Wednesday, April 24, 2024
Professional Services, Health, Pharmaceutical, Agriculture, Other Science, Natural Resources, Research, Fitness & Nutrition, Environment, Science, Finance, USD, Sale, Agreement, Climate change, Risk, Performance, License fee, Farmer, Photosynthesis, License, CAD, AC, Nutrient, Growth, FRA

"Securing the exclusive rights to distribute and sell the Agrarius product in North and South America, Central America, Mexico, and the Caribbean is viewed as a tremendous accomplishment and a major milestone for MVMD," explained Dennis Hancock, President & CEO of Mountain Valley MD.

Key Points: 
  • "Securing the exclusive rights to distribute and sell the Agrarius product in North and South America, Central America, Mexico, and the Caribbean is viewed as a tremendous accomplishment and a major milestone for MVMD," explained Dennis Hancock, President & CEO of Mountain Valley MD.
  • MVMD and AC will share equally in the guarantee such that MVMD will not be required to pay AC for the Agrarius product until the Performance Threshold has been met.
  • "The Performance Guarantee Program completely aligns our interests with those of our farming clients to ensure optimized crop performance while limiting the clients’ risk in this unique pay-for-performance model," continued Hancock.
  • The Agrarius product has been designed to activate a plants’ “defense mechanisms” at the cellular level, without the actual stress factor.

Encore Wire Reports First Quarter Results

Retrieved on: 
Tuesday, April 23, 2024
Other Manufacturing, Commercial Building & Real Estate, Construction & Property, Steel, Chemicals, Plastics, Building Systems, Manufacturing, Architecture, Other Construction & Property, Residential Building & Real Estate, Copper, Agreement, Aluminium, Pandemic, Investment, News, Depreciation, Security (finance), Plan, Disaster, Public expenditure, Emergency, Environment, Automation, Risk, GAAP, Video game

Encore Wire Corporation (NASDAQ Global Select: WIRE) (“Encore Wire” or the “Company”) today announced results for the first quarter of 2024.

Key Points: 
  • Encore Wire Corporation (NASDAQ Global Select: WIRE) (“Encore Wire” or the “Company”) today announced results for the first quarter of 2024.
  • Copper unit volume, measured in pounds of copper contained in the wire sold, increased 19.7% in the first quarter of 2024 versus the first quarter of 2023.
  • Copper unit volume, measured in pounds of copper contained in the wire sold, decreased 4.1% in the first quarter of 2024 versus the fourth quarter of 2023.
  • Commenting on the results, Daniel L. Jones, Chairman, President and Chief Executive Officer of Encore Wire Corporation, said, “We have experienced consistent, increased copper wire and cable demand from mid-2023, which continued through the first quarter of 2024.

New Found to Acquire Labrador Gold’s Kingsway Project

Retrieved on: 
Monday, April 22, 2024
Natural Resources, Other Natural Resources, Mining, Minerals, Sale, Agreement, AFZ, OTCQX, CDN, FNR, Acquisition, Transaction, Gold, Multimedia, TSX Venture Exchange, NFG

View the full release here: https://www.businesswire.com/news/home/20240422537394/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240422537394/en/
    Figure 1: Location of the Kingsway Project (Graphic: Business Wire)
    Greg Matheson, COO of New Found, stated: “The acquisition of the Kingsway Project announced today is a significant building block to the district scale potential of the Queensway Project.
  • Kingsway today is reminiscent of Queensway when New Found acquired the project back in 2016 with numerous early discoveries and large swaths of underexplored structures that later evolved into significant mineralized zones.
  • New Found’s base of geologic knowledge of the central Newfoundland Gold Belt and the AFZ will be applied to the Kingsway Project to expand on existing discovery areas and to identify additional mineralized zones.
  • New Found is well capitalized and has significant exploration infrastructure and an experienced exploration team in place that will allow for efficient exploration that is required to unlock the mineral potential at the Kingsway Project.

Ault Alliance Has Received an Investment of $44 Million to Date from Ault & Company under the November 2023 Securities Purchase Agreement

Retrieved on: 
Friday, April 19, 2024
Technology, Finance, Fintech, Professional Services, Blockchain, Software, Cryptocurrency, Data Management, Web3, Agreement, Investment, Partnership, Intelligence, Growth, Security (finance)

Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“Ault Alliance,” or the “Company”), today announced Ault & Company, Inc. (“Ault & Company”), an affiliate of the Company, has invested a total of $44.0 million pursuant to the Securities Purchase Agreement (the “Agreement”) entered into between the Company and Ault & Company on November 6, 2023.

Key Points: 
  • Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“Ault Alliance,” or the “Company”), today announced Ault & Company, Inc. (“Ault & Company”), an affiliate of the Company, has invested a total of $44.0 million pursuant to the Securities Purchase Agreement (the “Agreement”) entered into between the Company and Ault & Company on November 6, 2023.
  • To date, Ault & Company has purchased an aggregate of 44,000 shares of Series C convertible preferred stock (“Series C Preferred Stock”) and warrants (“Series C Warrants”) to purchase an aggregate of approximately 13.0 million shares of the Company.
  • Under the Agreement, as amended, Ault & Company can invest up to $75.0 million in the Series C Preferred Stock and Series C Warrants in multiple closings.
  • Ault & Company believes in the Company’s plans for growth and expects to make additional investments to support these key businesses.”
    Mr. Ault added that, “This partnership with Ault & Company reflects a shared vision for the future of Ault Alliance.

Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.

Retrieved on: 
Monday, April 15, 2024
Biotechnology, General Health, Pharmaceutical, Health, TDC, Agreement, Meeting, Sun Pharma, Proxy, Transaction, SPH, Sub, Form 6-K, Ordinary, Common stock, Private law, Person, Security (finance)

Following the Ordinary Class Meeting, a class meeting of the holders of the Company’s founders’ shares (the “Founder Shares”) will be held.

Key Points: 
  • Following the Ordinary Class Meeting, a class meeting of the holders of the Company’s founders’ shares (the “Founder Shares”) will be held.
  • If the Merger is completed, Taro will become a privately held company and its shares will no longer be listed on the NYSE.
  • If the Transactions are approved at the Meetings, it is expected that the Transactions will close in late June.
  • In connection with the Transactions, Taro will prepare and mail to its shareholders a proxy statement that will include a copy of the merger agreement.

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the AdaptHealth Securities Litigation

Retrieved on: 
Thursday, April 11, 2024
Class Action Lawsuit, Professional Services, Legal, Class Action, DFB, Notice, District court, Court, THIS, ALL, Hearing, Judgement, Market Street, Telephone, Agreement, JASON, FRANK, Prejudice, COMMON, ALAN, All

PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY.

Key Points: 
  • PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY.
  • §78u-4(a)(4) out of the Settlement Fund and, if so, in what amount; and (5) the Plan of Allocation should be approved by the Court as fair, reasonable and adequate.
  • The Court may decide to conduct the Final Approval Hearing by video or telephonic conference, or otherwise allow Settlement Class Members to appear at the hearing by phone, without further written notice to the Settlement Class.
  • IF YOU PURCHASED OR ACQUIRED ADAPTHEALTH SECURITIES BETWEEN NOVEMBER 8, 2019 AND JULY 16, 2021, INCLUSIVE, YOUR RIGHTS ARE AFFECTED BY THE SETTLEMENT OF THIS ACTION.

MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

Retrieved on: 
Thursday, April 11, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Agreement, Patient, Cancer, Mutation, CDK9, Venetoclax, Colorectal cancer, MEI, Bevacizumab, AML, Research, Cohort, Salvage therapy, Disease, Exercise, Therapy, IDH, Incidence, Neoplasm, Toxicity, Acute myeloid leukemia, FLT3, Standard of care, Death, Clinical trial, VEGF, Calendar, Pharmaceutical industry

With the MEI Board aligned around our strategy, we have a productive framework to advance both clinical programs in a manner intended to address significant medical needs while prioritizing a measured and objective-based allocation of our resources,” said David Urso, president and chief executive officer of MEI Pharma.

Key Points: 
  • With the MEI Board aligned around our strategy, we have a productive framework to advance both clinical programs in a manner intended to address significant medical needs while prioritizing a measured and objective-based allocation of our resources,” said David Urso, president and chief executive officer of MEI Pharma.
  • The plan builds on encouraging recently reported voruciclib clinical data and ME-344 data separately reported today.
  • Under the plan, the ongoing voruciclib development strategy will be guided by future clinical trial results and applicable regulatory authority advice.
  • The goal of the formulation effort is to increase biological activity, improve patient convenience of administration and increase commercial opportunity.

Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes

Retrieved on: 
Thursday, April 11, 2024
Health, Oncology, Medical Supplies, Debt-to-GDP ratio, Sale, Agreement, Retirement, Common stock, Finance Secretary (India), Note, Security (finance)

Exact Sciences Corp. (Nasdaq: EXAS) (the “Company”), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the “Agreements”) with certain holders of the Company’s 0.3750% Convertible Senior Notes due 2028 (the “Existing Notes”).

Key Points: 
  • Exact Sciences Corp. (Nasdaq: EXAS) (the “Company”), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the “Agreements”) with certain holders of the Company’s 0.3750% Convertible Senior Notes due 2028 (the “Existing Notes”).
  • The closing of the transaction is expected to occur on April 17, 2024, subject to customary closing conditions.
  • The New Notes will mature on April 15, 2031 (the “Maturity Date”), unless earlier repurchased, redeemed or converted.
  • K&L Gates LLP represented Exact Sciences Corporation and Kramer Levin Naftalis & Frankel LLP represented the placement agent in the transaction.